Skip to main content

Table 1 Baseline demographics and characteristics (ITT population)

From: Efficacy and tolerability of the investigational topical cream SD-101 (6% allantoin) in patients with epidermolysis bullosa: a phase 3, randomized, double-blind, vehicle-controlled trial (ESSENCE study)

 

SD-101 6%

n = 82

Vehicle

n = 87

Total

N = 169

Male, n (%)

49 (59.8)

39 (44.8)

88 (52.1)

Age, years

 Mean ± SD

13.8 ± 13.2

13.9 ± 13.1

13.9 ± 13.1

 Median

9.0

10.5

10.0

 Min, max

0.2, 67.0

0.2, 64.0

0.2, 67.0

Age group, n (%)

 1 month to <2 years

5 (6.1)

6 (6.9)

11 (6.5)

 2 years to <12 years

37 (45.1)

47 (54.0)

84 (49.7)

 12 years to <18 years

19 (23.2)

12 (13.8)

31 (18.3)

 ≥18 years

21 (25.6)

22 (25.3)

43 (25.4)

Race, n (%)

 White

69 (84.1)

72 (82.8)

141 (83.4)

 Black or African American

5 (6.1)

3 (3.4)

8 (4.7)

 Asian

4 (4.9)

8 (9.2)

12 (7.1)

 Other/not reported

4 (4.9)

4 (4.6)

8 (4.7)

Epidermolysis bullosa type, n (%)

 Simplex

10 (12.2)

8 (9.2)

18 (10.7)

 Recessive dystrophic

57 (69.5)

62 (71.3)

119 (70.4)

 Intermediate junctional

15 (18.3)

17 (19.5)

32 (18.9)

Diagnosis, n (%)

 Genetic testing

36 (43.9)

35 (40.2)

71 (42.0)

 Immunomapping

13 (15.9)

9 (10.3)

22 (13.0)

 Medical records

33 (40.2)

43 (49.4)

76 (45.0)

Target wound size, cm2, mean ± SD

18.8 ± 12.1

22.0 ± 31.7

20.4 ± 24.2

Target wound age, days, mean ± SD

406.5 ± 913.8

521.0 ± 1832.0

465.4 ± 1457.4

BSAi of lesional skin, %, mean ± SD

25.8 ± 19.4

24.4 ± 19.3

25.1 ± 19.3

BSAi of total body wound burden, %, mean ± SD

12.2 ± 12.6

10.5 ± 9.1

11.3 ± 11.0

Baseline itching scorea, mean ± SD

1.8 ± 1.21

2.0 ± 1.14

NC

Baseline pain scoreb, mean ± SD

3.1 ± 2.57

3.5 ± 2.88

NC

  1. BSAi body surface area index; ITT intent-to-treat; NC not calculated; SD standard deviation
  2. aScale from 0 to 4
  3. bScale from 0 to 10